# 503310878 05/18/2015

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3357496

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
VERTEX PHARMACEUTICALS (EUROPE) LIMITED	05/15/2015

### **RECEIVING PARTY DATA**

Name:	VERTEX PHARMACEUTICALS INCORPORATED	
Street Address:	50 NORTHERN AVENUE	
City:	BOSTON	
State/Country:	MASSACHUSETTS	
Postal Code:	02210	

## **PROPERTY NUMBERS Total: 2**

Property Type	Number	
Application Number:	14083693	
PCT Number:	US2013070693	

### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Email:** patents@vrtx.com

Correspondent Name: VERTEX PHARMACEUTICALS INCORPORATED

Address Line 1: 50 NORTHERN AVENUE

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	VPI/12-141 US & WO	
NAME OF SUBMITTER:	FRANCES M. CUNNINGHAM	
SIGNATURE:	/Frances M. Cunningham/	
DATE SIGNED:	05/18/2015	

**Total Attachments: 3** 

source=VPI\_12\_141USWO\_AssignmentUKtoUS#page1.tif source=VPI\_12\_141USWO\_AssignmentUKtoUS#page2.tif source=VPI\_12\_141USWO\_AssignmentUKtoUS#page3.tif

PATENT 503310878 REEL: 035659 FRAME: 0077

### ASSIGNMENT

We, Vertex Pharmaceuticals (Europe) Limited, a company registered in England and Wales under registered number 02907620 and having an office and a place of business at 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW U.K., for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of the Commonwealth of Massachusetts and having an office and a place of business at 50 Northern Avenue, Boston, Massachusetts 02210, its successors and assigns, all hereinafter referred to as the ASSIGNEE:

- (1) the entire right, title and interest in all countries throughout the world in and to any and all of my/our inventions, and discoveries disclosed in:
- (a) the application for United States Letters Patent entitled: COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE, and filed in the United States Patent and Trademark Office on November 19, 2013, under Application Number 14/083,693, including any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisions thereof, and any substitute applications therefor, and/or
- (b) the International Patent Application entitled: COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE, filed under the Patent Cooperation Treaty in the United States Receiving Office on November 19, 2013, under Application No. PCT/US213/70693, and designating all countries, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor;
- (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my/our names at the election of the ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in any country throughout the world;
- (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in any country throughout the world, and in and to any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof; and
- (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in

and to the above inventions, discoveries and applications including, but not limited to, the following priority application(s):

61/757,764	USA	January 29, 2013
Application No.	Country	Filing Date
61/728,333	USA	November 20, 2012
Application No.	Country	Filing Date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of the ASSIGNEE to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

By: Ken
Kerry A. Hynn
Vice President and Chief IP Counsel
on behalf of Vertex Pharmaceuticals (Europe) Limited
Date: May 15, 2015
V
Commonwealth of Massachusetts
County of Suffolk
On this
France M. Cunningham
Notary Public
My Commission Expires: $\frac{\delta 11/\sqrt{2018}}{2018}$

